Home > DocuBase > Article
« All DocuBase Articles
Wednesday, 12th January 2011
Medicare Payments for Newly Available Generic Drugs
Medicare Payments for Newly Available Generic Drugs (PDF)
Source: U.S. Department of Health and Human Services, Office of Inspector General
Medicare and its beneficiaries could have saved an estimated $111 million had payment amounts reflected actual sales prices during the initial generic availability of 16 drugs. These potential savings accounted for 25 percent of total expenditures for these drugs during the same period.
Manufacturers are required to submit average sales price (ASP) data to CMS within 30 days after the close of each quarter, and those data are used to calculate the payment amounts for the following quarter. As a result, there is a two-quarter lag between when sales occur and when the payment amounts reflect those sales. This reimbursement lag is especially problematic when newly available generic drugs enter the market, as their ASPs are often substantially lower than their brand counterparts, but payment amounts remain at the higher brand level for two quarters or more.
We found that payment amounts were significantly higher than market prices for an extended period for the newly available generic drugs under review. In other words, during the period of initial generic availability, generic versions of these drugs were being administered or dispensed to beneficiaries, but Medicare was still paying brand prices. Furthermore, according to the Food and Drug Administration, 26 of the 48 brand-only drugs with the highest Part B expenditures in 2008 could have first generic versions approved in the next several years, meaning that the vulnerability posed by the two-quarter lag likely will continue to grow. Nearly half of the current high-dollar brand-only Part B drugs are biologics, which (because of recent legislation) may also gain approval in generic form. Compounding the problem of the two-quarter lag are the significant obstacles that remain in identifying in advance when generic versions of drugs will become available. Because of issues such as patent litigation and the generic manufacturers' timeliness in reporting ASPs, it is difficult to predict when first-generic versions will reach the market.
We recommend that CMS work with Congress to require manufacturers of first generics to submit monthly ASP data during the period of initial generic availability. This could substantially reduce the two-quarter lag and make Medicare payment amounts more reflective of actual market prices. If CMS finds this to be an effective means for alleviating the financial impact of the two-quarter lag, the agency may wish to consider requiring monthly ASP submissions for all Part B-covered drugs.
CMS did not concur with our recommendation, citing potential problems with manufacturer price submissions and increased administrative burdens under a proposed monthly ASP reporting requirement. CMS also stated that it believes the two-quarter lag protects Medicare and its beneficiaries from unchecked price increases and is an incentive for faster generic utilization. We believe that the savings from a reduced reimbursement lag may outweigh any issues involved with implementing a monthly ASP reporting system. Furthermore, we note that the ASP-based reimbursement system (in which all versions of a drug assigned to one payment code are paid at the same amount) is a natural incentive for manufacturers to limit rapid price increases, as well as for providers to utilize generic versions.
Please note: DocuTicker's editors collect citations for full-text PDF reports freely available on the web but we do not archive these reports. When you click a link to find and/or download the report, you are leaving the DocuTicker site. DocuTicker makes no representations regarding the ongoing availability of any report or any external resource. Links were accurate as of the date of posting.
« All DocuBase Articles
FreePint supports the value of information in the enterprise. Read more »
Latest FreePint Content:
Product Review of LexisNexis Company Dossier (Value - Competitors, Development & Pricing)
Tuesday, 2nd September 2014
In the final part of his review of LexisNexis Company Dossier, author Chris Porter considers what kinds of research needs it best meets and how its data and functionality stack up against some of its major competitors in the company information field. The service contains information on around 80 million companies and around 75 million business executives.
Subscription Update for Information Services Management
Tuesday, 2nd September 2014
The monthly FreePint Report: Subscription Update for Information Services Management has been published, which highlights product reviews, source updates and news & analysis relevant to those responsible for information service management, information strategy and content procurement.
Product Review of LexisNexis Company Dossier (Technology - Search, Outputs & Alerts, User Interface & Help)
Monday, 1st September 2014
The third part of Chris Porter's review looks at the searching, filtering, list-building and exporting capabilities within LexisNexis Company Dossier, a research database providing information about companies, executives and industries. His scrutiny includes the "Compare Companies" feature and "Custom Report" tool.
- ... more ...
All FreePint Content »
FreePint Topics »
A FreePint Subscription delivers articles and reports that support your organisation's information practice, content and strategy.
Find out more and order a FreePint Subscription by visiting the
completing our online form: Subscription Order page.
"As a service providing practical support and guidance for what professionals do FreePint is pretty unique and decent value for money." ..."
Read more testimonials and supply yours »